{"log_id": 797248020026271993, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0, "average": 0.829894, "min": 0.829894}, "location": {"width": 34, "top": 160, "height": 36, "left": 1616}, "words": "道"}, {"probability": {"variance": 0.012141, "average": 0.949315, "min": 0.593566}, "location": {"width": 1138, "top": 201, "height": 43, "left": 233}, "words": "为临床推荐口服剂量的10和40倍)时,前胃出现良性鳞状细胞乳头状瘤和恶性状细胞痛"}, {"probability": {"variance": 0.006984, "average": 0.954039, "min": 0.671535}, "location": {"width": 1138, "top": 246, "height": 41, "left": 233}, "words": "泮托拉唑还导致极少数大鼠出现胃肠道肿瘤,包括50mg/Kgd剂量时偶尔出现十二指肠癌"}, {"probability": {"variance": 0.037066, "average": 0.871347, "min": 0.392643}, "location": {"width": 1168, "top": 290, "height": 43, "left": 230}, "words": "以及200mg/Kgl剂量时胃底出现良性息肉和腺涵泮托拉唑给药剂量O.520mgg/d时,大"}, {"probability": {"variance": 0.023666, "average": 0.900597, "min": 0.48433}, "location": {"width": 1166, "top": 333, "height": 45, "left": 230}, "words": "鼠剂量依赖地出现肝细胞腺癌和肝癌,201mg/kg/d剂量还可使大鼠甲状腺囊泡细胞瘤和囊泡"}, {"probability": {"variance": 0.019883, "average": 0.931439, "min": 0.410077}, "location": {"width": 1076, "top": 377, "height": 45, "left": 233}, "words": "细胞癌的发生率增加。SD大鼠6个月和12个月的毒性研究中也偶见细腺痘和肝癌"}, {"probability": {"variance": 0.010683, "average": 0.947025, "min": 0.491136}, "location": {"width": 1113, "top": 420, "height": 41, "left": 288}, "words": " Fischer34大鼠连续24个月经口给予泮托拉唑5~50mg/Kg/d(按体表面积折算,为临床推"}, {"probability": {"variance": 0.008987, "average": 0.952266, "min": 0.57599}, "location": {"width": 1170, "top": 466, "height": 43, "left": 228}, "words": "荐口服剂量的1-10倍),胃底剂量依赖性出现肠嗜铬样细胞增生及良性和恶性的神经内分泌细"}, {"probability": {"variance": 0.01218, "average": 0.957876, "min": 0.417899}, "location": {"width": 909, "top": 512, "height": 38, "left": 228}, "words": "胸瘤。但该试验的剂选择不足以支持对泮托拉唑潜在致癌性的充分评"}, {"probability": {"variance": 0.017932, "average": 0.922204, "min": 0.443105}, "location": {"width": 1099, "top": 551, "height": 41, "left": 297}, "words": "3C3F1小鼠连续24个月经口服给予托拉坐5~150mg/Kg(按体表面积折算,为临床"}, {"probability": {"variance": 0.008947, "average": 0.946857, "min": 0.564766}, "location": {"width": 1150, "top": 596, "height": 38, "left": 228}, "words": "推荐口服剂量的0.5~15倍),同样出现胃底嗜铬栏细胞增生:雌鼠在150 mg/Kg/d剂量时,"}, {"probability": {"variance": 0.02232, "average": 0.951042, "min": 0.413805}, "location": {"width": 404, "top": 647, "height": 32, "left": 226}, "words": "肝跑腺瘤和肝癌的发生率升高"}, {"probability": {"variance": 0.014716, "average": 0.945449, "min": 0.496014}, "location": {"width": 1111, "top": 683, "height": 43, "left": 288}, "words": "上述啮齿类动物的致癌性研究结果提示本品具有一定的致璃性,但此结果与临床的相关性"}, {"probability": {"variance": 0.000116, "average": 0.991809, "min": 0.973227}, "location": {"width": 116, "top": 733, "height": 36, "left": 228}, "words": "尚不清楚"}, {"probability": {"variance": 0.063471, "average": 0.813712, "min": 0.446899}, "location": {"width": 166, "top": 777, "height": 34, "left": 235}, "words": "【药代动力学"}, {"probability": {"variance": 0.007208, "average": 0.953765, "min": 0.629365}, "location": {"width": 1088, "top": 813, "height": 41, "left": 283}, "words": "泮托拉唑血药峰浓度(Cx>和血药浓度-时间曲线下面积(AUC)与10mg至80mg静"}, {"probability": {"variance": 0.017918, "average": 0.949698, "min": 0.362265}, "location": {"width": 1147, "top": 859, "height": 41, "left": 221}, "words": "脉注射给药剂量增加成比例。泮托拉唑不积且每日多饮给药不改变其药代动力学性质。静"}, {"probability": {"variance": 0.017457, "average": 0.930594, "min": 0.482859}, "location": {"width": 1147, "top": 903, "height": 38, "left": 221}, "words": "脉注射托拉唑钠后,其血药,度快速下降,消除半衰期约为一小时,在CYP2C19幕因强"}, {"probability": {"variance": 0.039529, "average": 0.882818, "min": 0.377753}, "location": {"width": 1147, "top": 946, "height": 41, "left": 221}, "words": "代谢型月开功能正常的人群中,十五分钟内恒速静脉注射群托拉唑钠1ng的量,峰浓度"}, {"probability": {"variance": 0.020273, "average": 0.901986, "min": 0.376858}, "location": {"width": 1131, "top": 987, "height": 43, "left": 237}, "words": "(C为5.52±1.421g/ml,血药浓度时间的总曲线面积为4+15 u p h, mi,总清除率为"}, {"probability": {"variance": 0.036257, "average": 0.882902, "min": 0.424158}, "location": {"width": 162, "top": 1042, "height": 29, "left": 224}, "words": "7.6~14.0Lh"}, {"probability": {"variance": 0, "average": 0.998924, "min": 0.998383}, "location": {"width": 64, "top": 1083, "height": 34, "left": 221}, "words": "分布"}, {"probability": {"variance": 0.008017, "average": 0.93892, "min": 0.65041}, "location": {"width": 1088, "top": 1120, "height": 41, "left": 281}, "words": "泮托拉的表观分布容积约为11023.61主要分布红胞外液。泮拉唑的血清蛋白"}, {"probability": {"variance": 0.006341, "average": 0.967835, "min": 0.708054}, "location": {"width": 384, "top": 1168, "height": 36, "left": 219}, "words": "结合率约9%,主要为蛋白"}, {"probability": {"variance": 0, "average": 0.999253, "min": 0.998648}, "location": {"width": 61, "top": 1214, "height": 34, "left": 221}, "words": "代谢"}, {"probability": {"variance": 0.016943, "average": 0.934966, "min": 0.50849}, "location": {"width": 1088, "top": 1250, "height": 41, "left": 281}, "words": "洋托拉唑广泛在肝通过细胞色素P450(CYP)系统代谢:药物代谢与给药途径(静脉"}, {"probability": {"variance": 0.01602, "average": 0.943982, "min": 0.4053}, "location": {"width": 1150, "top": 1298, "height": 38, "left": 217}, "words": "给药或口服)无关,主要代谢途径是由CYP2C19基因去甲基化后硫酸化,其他代谢径包括"}, {"probability": {"variance": 0.008564, "average": 0.949939, "min": 0.580697}, "location": {"width": 1143, "top": 1339, "height": 45, "left": 219}, "words": "通过CYP3A4氧化,没有证据表明泮打拉唑代谢物有显著的药理活性CYP2C19因一些亚"}, {"probability": {"variance": 0.00941, "average": 0.948065, "min": 0.613582}, "location": {"width": 1150, "top": 1383, "height": 41, "left": 219}, "words": "群的缺失而具遗传多态性(例如,3%的白种人和非裔美国人以及17%~23%的亚洲人),虽"}, {"probability": {"variance": 0.032308, "average": 0.900727, "min": 0.35639}, "location": {"width": 1147, "top": 1424, "height": 48, "left": 219}, "words": "然亚缓慢代泮托拉唑的消除半衰期值为3.5到10.0小时,但他们每天给药一一次,蓄积很"}, {"probability": {"variance": 0.048117, "average": 0.849439, "min": 0.384408}, "location": {"width": 157, "top": 1476, "height": 29, "left": 219}, "words": "少(23%)"}, {"probability": {"variance": 0.002646, "average": 0.948126, "min": 0.896683}, "location": {"width": 64, "top": 1518, "height": 34, "left": 219}, "words": "排泄"}, {"probability": {"variance": 0.011663, "average": 0.944105, "min": 0.453908}, "location": {"width": 1081, "top": 1556, "height": 45, "left": 285}, "words": "CYP2C19基因强代谢型人群单剂量静泳注射1C标记的浮托拉唑钠后,约71%的剂量从"}, {"probability": {"variance": 0.020547, "average": 0.946342, "min": 0.442277}, "location": {"width": 919, "top": 1602, "height": 38, "left": 217}, "words": "尿中排出以及8%通过胆汁泄由粪便排出,无浮托拉唑原型从肾出"}, {"probability": {"variance": 0.001138, "average": 0.965842, "min": 0.932102}, "location": {"width": 64, "top": 1648, "height": 36, "left": 217}, "words": "老年"}, {"probability": {"variance": 0.005961, "average": 0.954928, "min": 0.632965}, "location": {"width": 1088, "top": 1689, "height": 43, "left": 278}, "words": "老年人(65至7岁)连续静脉给药后,泮托拉唑的曲线下面积和消除兰衰期值与在年"}, {"probability": {"variance": 0.010177, "average": 0.950275, "min": 0.643426}, "location": {"width": 777, "top": 1735, "height": 41, "left": 214}, "words": "轻受试者中观察到的相似,因而对老年患者,不建议调整剂量"}, {"probability": {"variance": 5.8e-05, "average": 0.990921, "min": 0.983324}, "location": {"width": 64, "top": 1783, "height": 34, "left": 217}, "words": "性别"}, {"probability": {"variance": 0.00443, "average": 0.967932, "min": 0.641362}, "location": {"width": 1090, "top": 1819, "height": 45, "left": 278}, "words": "口给药后,女性中的泮托拉唑曲线下面积和血药峰浓度较另性有适度增加,但体重调"}, {"probability": {"variance": 0.003005, "average": 0.969673, "min": 0.763902}, "location": {"width": 777, "top": 1865, "height": 41, "left": 214}, "words": "整后男性和女性的清除率相似,因而没必要就性别而调整剂量"}, {"probability": {"variance": 1e-05, "average": 0.997903, "min": 0.991717}, "location": {"width": 155, "top": 1915, "height": 32, "left": 214}, "words": "肾功能不全"}, {"probability": {"variance": 0.010674, "average": 0.970943, "min": 0.374075}, "location": {"width": 1092, "top": 1950, "height": 50, "left": 274}, "words": "严重肾功能不全患者的泮托拉唑药代动力学参数与正常人类似。对肾功能衰患者或血"}, {"probability": {"variance": 0.004764, "average": 0.959436, "min": 0.80164}, "location": {"width": 379, "top": 2002, "height": 36, "left": 214}, "words": "液透听的患者,无需调整剂量"}, {"probability": {"variance": 5.1e-05, "average": 0.995379, "min": 0.98108}, "location": {"width": 153, "top": 2046, "height": 34, "left": 214}, "words": "肝功能不全"}, {"probability": {"variance": 0.031524, "average": 0.901508, "min": 0.388918}, "location": {"width": 1095, "top": 2082, "height": 43, "left": 274}, "words": "在轻度至重度肝功能不全患者开硬化患老 child-pugh分级AC)二托拉唑后,最"}], "language": 3}